• Molecular NameIdoxuridine
  • Synonym5IDU; 5IUDR; Allergan 201; Allergan 211; ID2; Idossuridina [DCIT]; Idoxuridin; Idoxuridina [INN-Spanish]; Idoxuridinum [INN-Latin]; IDU; IDUR; Iododeoxyridine; Iodoxuridine; IUDR
  • Weight354.1
  • Drugbank_IDDB00249
  • ACS_NO54-42-2
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)-0.84
  • pka8.3
  • LogD (pH=7, predicted)-0.91
  • Solubility (experiment)10 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-2.07
  • LogSw (predicted, AB/LogsW2.0)14.95
  • Sw (mg/ml) (predicted, ACD/Labs)2.7
  • No.of HBond Donors3
  • No.of HBond Acceptors7
  • No.of Rotatable Bonds2
  • TPSA99.1
  • StatusFDA approved
  • AdministrationIntravenously
  • PharmacologyAn anti-herpesvirus antiviral drug.
  • Absorption_valueN/A
  • Absorption (description)Systemic absorption is unlikely following ocular administration even when nasolacrimal secretions are swallowed, since vidarabine is rapidly deaminated in the gastrointestinal tract.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmIdoxuridine is rapidly inactivated by deaminases or nucleotidases.
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityHypersensitivity or increased sensitivity of eyes to light.
  • LD50 (rat)N/A
  • LD50 (mouse)LD50=3080 mg/kg